10-Q: TruBridge Q3 2025: Net Income Soars, Revenue Grows 2%

TruBridge, Inc. reports a significant financial turnaround in Q3 2025, achieving net income of $5.6 million and a 2% revenue increase, driven by cost optimization and SaaS growth.

Summary

• Net income for Q3 2025 was $5.6 million ($0.37 per share), a substantial improvement from a net loss of $9.1 million ($0.61 per share) in Q3 2024.
• Net income for the nine months ended September 30, 2025, was $8.6 million ($0.58 per share), compared to a net loss of $15.4 million ($1.04 per share) in the same period of 2024.
• Total revenues increased by $1.4 million (2%) to $86.1 million in Q3 2025 compared to Q3 2024.
• Total revenues for the nine months increased by $4.6 million (2%) to $259.0 million compared to the same period in 2024.
• Financial Health segment revenues decreased slightly by $0.2 million in Q3 2025 but increased by $2.3 million (1%) for the nine months.
• Patient Care segment revenues increased by $1.6 million (5%) in Q3 2025 and by $2.3 million (3%) for the nine months.
• Operating income for Q3 2025 was $4.1 million, up from $2.8 million in Q3 2024. For the nine months, operating income was $15.9 million, a significant increase from $0.08 million in 2024.
• Adjusted EBITDA increased by 11% to $16.3 million in Q3 2025 and by 25% to $48.2 million for the nine months.
• A material weakness in internal control over financial reporting related to revenue recognition processes continues as of September 30, 2025.
• Chief Technology & Innovation Officer, Wes D. Cronkite, will depart effective December 5, 2025.
• The company is involved in an accounting arbitration with VG Sellers, Inc. regarding an earnout provision from the Viewgol acquisition, with VG Sellers seeking the maximum amount.

Sentiment

Score: 7

Explanation: The company demonstrated a strong financial turnaround with a shift from net losses to net income and improved profitability metrics (operating income, Adjusted EBITDA). Revenue growth, while modest, was positive across both segments. However, the persistent material weakness in internal controls, declining bookings (especially net-new), and the departure of a key executive temper the overall positive sentiment. The legal dispute over an earnout and potential impacts from healthcare legislation also add a layer of uncertainty.

Positives

• Achieved a significant turnaround from net loss to net income for both the three and nine months ended September 30, 2025.
• Total revenues increased by 2% for both the three months ($86.1 million) and nine months ($259.0 million) ended September 30, 2025.
• Patient Care segment revenues increased by $1.6 million (5%) in Q3 2025 and by $2.3 million (3%) for the nine months, driven by EHR installations and new SaaS contracts.
• Adjusted EBITDA increased by 11% to $16.3 million in Q3 2025 and by 25% to $48.2 million for the nine months, indicating improved operational efficiency.
• Total costs of revenues (exclusive of amortization and depreciation) decreased as a percentage of total revenues (from 50% to 49% in Q3, and 50% to 47% year-to-date).
• Interest expense decreased due to a reduction in the outstanding balance of the revolving credit facility and a lower interest rate.
• Net cash provided by operating activities increased by $6.3 million to $28.1 million for the nine months ended September 30, 2025.
• The One Big Beautiful Bill Act (OBBBA) reduced the company's 2025 expected current tax liability, resulting in a current tax benefit for the three and nine months ended September 30, 2025.
• Patient Care customer retention rate for the last twelve months was 93.8%, with the flagship TruBridge EHR product achieving 96.5%.

Negatives

• Financial Health revenues decreased by $0.2 million in Q3 2025, primarily due to customer attrition.
• Financial Health Adjusted EBITDA decreased by 11% in Q3 2025, attributed to customer attrition and increased product development costs.
• Total bookings decreased by $5.4 million (26%) in Q3 2025 and by $4.7 million (7%) for the nine months, driven by delays in customer decisions for net-new bookings in both segments.
• Net-new bookings for Financial Health decreased by $4.5 million (79%) in Q3 and $6.9 million (37%) year-to-date (excluding Viewgol).
• Net-new bookings for Patient Care decreased by $1.7 million (95%) in Q3.
• Cross-sell bookings for Patient Care decreased by $0.7 million (11%) in Q3 and $4.8 million (25%) year-to-date.
• The sunset of the Centriq product continues to impact Patient Care revenue, accounting for $0.9 million in Q3 2025 compared to $1.8 million in Q3 2024.
• A material weakness in internal control over financial reporting related to revenue recognition processes persists as of September 30, 2025.
• A legal dispute with VG Sellers, Inc. is ongoing, with VG Sellers seeking the maximum earnout amount from the Viewgol acquisition, which the company firmly believes is not due.
• The Chief Technology & Innovation Officer, Wes D. Cronkite, will depart effective December 5, 2025.

Risks

• Saturation of the target market and hospital consolidations.
• Unfavorable economic or market conditions that may cause a decline in spending for information technology and services.
• Significant legislative and regulatory uncertainty in the healthcare industry, including impacts from the One Big Beautiful Bill Act (OBBBA) effective in 2027 and 2028.
• Exposure to liability for failure to comply with regulatory requirements.
• Challenges in the transition to a subscription-based recurring revenue model and modernization of technology.
• Competition with companies that have greater financial, technical, and marketing resources.
• Potential future acquisitions that may be expensive, time-consuming, and subject to inherent risks.
• Inability to attract and retain qualified personnel in a global workforce.
• Disruption from periodic restructuring of the sales force.
• Slower than anticipated development of the market for Financial Health services.
• Potential inability to manage growth in new markets.
• Potential failure to effectively implement a new enterprise resource planning software solution.
• Exposure to numerous and often conflicting laws, regulations, policies, standards, or other requirements through domestic and international business activities.
• Potential litigation and investigations, including the ongoing earnout dispute with VG Sellers, Inc.
• Reliance on offshore third-party resources.
• Competitive and litigation risk related to the use of artificial intelligence.
• Potential failure to develop new products or enhance current products that keep pace with market demands.
• Exposure to claims if products fail to provide accurate and timely information for clinical decision-making.
• Exposure to claims for breaches of security and viruses in systems.
• Undetected errors or problems in new products or enhancements.
• Inability to convince customers to migrate to current or future releases of products.
• Failure to maintain margins and service rates, or an increase in lower-margin service revenues.
• Exposure to liability in the event of providing inaccurate claims data to payors or from software licensing and service provision.
• Dependence on licenses of rights, products, and services from third parties.
• Failure to protect intellectual property rights or exposure to significant license fees or damages for infringement.
• Service interruptions resulting from loss of power and/or telecommunications capabilities.
• Potential inability to secure additional financing on favorable terms to meet future capital needs.
• Substantial indebtedness that may adversely affect business operations and pressures on cash flow to service debt.
• Restrictive terms of the credit agreement on current and future operations.
• Changes in and interpretations of financial accounting matters that govern the measurement of performance.
• The potential for goodwill or intangible assets to become impaired.
• Quarterly fluctuations in financial results due to various factors.
• Volatility in stock price.
• Failure to maintain effective internal control over financial reporting, as a material weakness persists.
• Inherent limitations in internal control over financial reporting.
• Vulnerability to significant damage from natural disasters.
• Exposure to market risk related to interest rate changes, particularly SOFR fluctuations.
• Potential material adverse effects due to macroeconomic conditions.
• The company does not anticipate paying dividends on its common stock.
• Actions of activist stockholders against the company could be disruptive and costly, or potentially cause uncertainty about the strategic direction of the business.
• A partial federal government shutdown effective October 1, 2025, could cause delays in payment for services rendered to customers.

Future Outlook

The company expects the trend of customer demand shifting towards a Software as a Service (SaaS) license model to continue, which will place downward pressure on short-term revenue growth and profitability metrics but benefit long-term revenue growth and profitability. The company plans to release its first denials prediction model using AI during the first quarter of 2026. Supplemental federal and state guidance is expected to be issued to implement the various provisions of the One Big Beautiful Bill Act (OBBBA), many of which have effective dates in 2027 and 2028. The company believes its efforts towards margin optimization are well-timed to respond to wage inflation but cannot guarantee these efforts will fully eliminate related margin deterioration.

Management Comments

• "Our core strategy is to achieve meaningful long-term revenue growth by cross-selling Financial Health services into our existing Patient Care customer base, expanding Financial Health market share with sales to new hospitals and larger health systems, and pursuing competitive Patient Care takeaway opportunities in the acute care markets."
• "Our growth strategy is heavily dependent on our ability to cross-sell Financial Health services into our Patient Care customer base. Therefore, retention of our existing Patient Care customers is a key component of our long-term growth strategy."
• "We are placing ever-increasing value in further developing our already significant recurring revenue base to further stabilize our revenues and cash flows."
• "We see both the value and risk of generative AI being leveraged in healthcare delivery and are committed to ensuring our client population is not left behind as this rapidly advancing technology is being implemented and adopted."
• "We believe healthcare IT will be an area of continued investment due to its unique potential to improve safety and efficiency and reduce costs while meeting current and future regulatory, compliance, and government reimbursement requirements."
• "The shift in customer preference and the Company's turn towards SaaS arrangements has significantly reduced the frequency of new financing arrangements for customer purchases under a perpetual license."
• "This naturally places downward pressure on short-term revenue growth and profitability metrics, but benefits long-term revenue growth and profitability which, in our view, is consistent with our goal of delivering long-term shareholder value."
• "We believe that our efforts towards margin optimization are well-timed, enabling a rapid response to actual or expected wage inflation in order to preserve Financial Health profitability, but we cannot guarantee that these efforts will fully eliminate any related margin deterioration."
• "Management does not believe it is reasonably possible that such matters [routine litigation] will have a material adverse effect on the Company's financial statements."
• "The Company firmly believes that no earnout amount is due to VG Sellers, Inc. pursuant to the Securities Purchase Agreement."
• "The Company intends to vigorously defend its positions on the issues."

Industry Context

The healthcare industry is significantly influenced by U.S. regulatory and national health initiatives, driving a shift towards value-based reimbursement and increasing demand for healthcare IT solutions to reduce costs and improve quality. The company's target market of rural and community hospitals is highly reliant on Medicare, Medicaid, and third-party payer reimbursement, making them vulnerable to changes in government programs. The recently enacted One Big Beautiful Bill Act (OBBBA) is expected to impact healthcare providers through changes to Medicaid and the Affordable Care Act, potentially reducing funding and increasing regulatory burdens, with most provisions effective in 2027 and 2028. The industry is also seeing a broad trend towards SaaS models for healthcare IT, as clients seek advanced software with lower initial capital outlays. The company's involvement in the TRAIN (Trustworthy and Responsible AI Network) highlights an industry-wide focus on safely integrating AI into healthcare delivery.

Management Changes

Corporate Governance

Legal Proceedings

• Routine litigation that arises in the ordinary course of business, which management does not believe will have a material adverse effect on financial statements.
• Request from VG Sellers, Inc. for accounting arbitration concerning earnout provisions from the October 16, 2023, Securities Purchase Agreement for the acquisition of Viewgol, LLC. VG Sellers, Inc. seeks the maximum earnout amount.
• VG Sellers, Inc. also threatened to commence litigation concerning the earnout provisions.
• The company firmly believes no earnout amount is due and intends to vigorously defend its positions.
• The company is currently unable to estimate the potential liability due to the significant number of legal, accounting, and factual issues.

Stakeholder Impact

• Shareholders: Positive impact from improved net income and Adjusted EBITDA, but potential concerns from declining bookings, material weakness in internal controls, and the legal dispute. The departure of a key executive could also be a concern. The termination of the Rights Agreement removes a potential dilutive event.
• Employees: Impacted by cost savings initiatives, including severance costs (though lower than prior year). Stock-based compensation plans are in place for executive officers and key employees. Departure of Chief Technology & Innovation Officer.
• Customers: Patient Care customers are shifting to SaaS models, which are attractive due to lower initial capital outlay. Financial Health customers experienced attrition. Potential payment delays for rural hospital customers due to government shutdown.
• Creditors: Debt levels are decreasing, and the company was in compliance with financial covenants as of September 30, 2025, which is positive.
• Suppliers: Contracts with third-party suppliers and vendors may include annual price adjustments indexed to inflation rates, potentially impacting costs.

Next Steps

• Continue to implement customer contract life cycle management tools to address the material weakness in internal control over financial reporting.
• Strengthen the company's finance team and build strong communication channels between functions.
• Monitor the impacts of the federal government shutdown on operations and financials.
• Vigorously defend its position in the accounting arbitration with VG Sellers, Inc. regarding the Viewgol earnout provisions.
• Release the first denials prediction model (AI-based) to the public during the first quarter of 2026.
• Evaluate the impact of adopting new accounting standards: ASU 2023-09 (effective for fiscal years beginning after December 15, 2024), ASU 2024-03 (effective for fiscal years beginning after December 15, 2026), and ASU 2025-06 (effective for fiscal years beginning after December 15, 2027).

Key Dates

Recommendation

The company has shown a commendable turnaround in profitability, moving from significant losses to net income, and demonstrating improved operational efficiency through higher Adjusted EBITDA. Revenue growth, particularly in the Patient Care segment driven by SaaS adoption, is a positive indicator of strategic alignment with market trends. The reduction in debt and compliance with covenants also provide financial stability. However, several factors warrant caution. The persistent material weakness in internal controls over financial reporting is a serious concern that needs full remediation. The decline in total bookings, especially net-new bookings in both segments, suggests challenges in sales generation and future revenue pipeline. The legal dispute over the Viewgol earnout adds financial uncertainty, and the departure of the Chief Technology & Innovation Officer could impact future innovation efforts. Given the mixed signals – strong financial recovery offset by operational and governance challenges – a "Hold" recommendation is appropriate. Investors should monitor the remediation of internal controls, booking trends, and the outcome of the legal proceedings before considering further investment.

Keywords

Healthcare IT, Revenue Cycle Management, Electronic Health Records, Financial Health, Patient Care, SaaS, Quarterly Report, SEC Filing, Financial Performance, Adjusted EBITDA, Internal Controls, Corporate Governance, Risk Factors, Artificial Intelligence, Healthcare Regulation, Debt, Stock-based compensation